This article is a working preliminary draft, NOT yet submitted for peer review. Leave your comments on the discussion page (talk page) or contact the First Author, BirenSaraiya, at their talk page or by email.

Return to Journal of South Asian Health

CAD and Platelet Dysfunction

Introduction[edit | edit source]

Treatment of Acute Coronary Syndrome (ACS) involves many of the platelet modulating drugs such as Aspirin, GPIIb/IIIa inhibitors.

Primary Prevention of Coronary Artery Disease includes Aspirin. Secondary Prevention of CAD includes Aspirin.

Though the current models for atherosclerosis does not revolve around platelet abnormalities: the question raised here is: 1. Are there any platelet speicific pathophysiology that predispose one to have ACS. 2. Are there any interventions (other than Aspirin) that are specifically related to platelets for primary/secondary prevention.

We will first review: 1. Platelet physiology 2. Atherosclerosis physiology

Epidemiology[edit | edit source]

Genetics[edit | edit source]

Pathophysiology[edit | edit source]

Clinical Presentation[edit | edit source]

Diagnostics[edit | edit source]

Treatment[edit | edit source]

Prognosis[edit | edit source]

Associated Diseases and complications[edit | edit source]

Bibliography[edit | edit source]

Further research suggestions/Discussion[edit | edit source]

Community content is available under CC-BY-SA unless otherwise noted.